(Q26859134)

English

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

scientific article

In more languages

Statements

scholarly article

1 reference

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (English)

1 reference

rheumatoid arthritis

4 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

17

0 references

7

0 references

4

object named as

Maya Buch

1 reference

Cécile Gaujoux-Viala

8

object named as

Cécile Gaujoux-Viala

1 reference

Marieke Scholte-Voshaar

29

object named as

Marieke Scholte-Voshaar

1 reference

Désirée van der Heijde

33

object named as

Désirée van der Heijde

0 references

Robert Landewé

2

object named as

Robert Landewé

1 reference

Andrea Rubbert-Roth

28

object named as

Andrea Rubbert-Roth

1 reference

Frank Buttgereit

18

object named as

Frank Buttgereit

0 references

object named as

Karel Pavelka

26

0 references

Maxime Dougados

6

object named as

Maxime Dougados

1 reference

24

object named as

Tore K Kvien

1 reference

1

object named as

Josef S Smolen

1 reference

9

object named as

Laure Gossec

1 reference

Maurizio Cutolo

20

object named as

Maurizio Cutolo

1 reference

11

object named as

Sofia Ramiro

1 reference

19

object named as

Bernard Combe

1 reference

14

object named as

Daniel Aletaha

1 reference

Xavier Mariette

25

object named as

Xavier Mariette

1 reference

Gerd-Rüdiger Burmester

5

object named as

Gerd Burmester

1 reference

Kevin L Winthrop

12

object named as

Kevin Winthrop

1 reference

Johanna M. W. Hazes

22

object named as

Johanna M W Hazes

1 reference

Piet L C M van Riel

27

object named as

Piet L C M van Riel

1 reference

Neil Betteridge

15

object named as

Neil Betteridge

1 reference

Johannes Jw Bijlsma

16

object named as

Johannes W J Bijlsma

1 reference

Marios Kouloumas

23

object named as

Marios Kouloumas

1 reference

13

object named as

Maarten de Wit

1 reference

author name string

Ferdinand C Breedveld

3

1 reference

Jackie Nam

10

1 reference

Nemanja Damjanov

21

1 reference

David L Scott

30

1 reference

Tuulikki Sokka-Isler

31

1 reference

John B Wong

32

1 reference

language of work or name

1 reference

publication date

March 2014

1 reference

1 March 2014

4 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

Annals of the Rheumatic Diseases

5 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

73

1 reference

492-509

1 reference

3

1 reference

copyright license

Creative Commons Attribution-NonCommercial

4 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

21 March 2017

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

21 March 2017

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

21 March 2017

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

21 March 2017

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

21 March 2017

The new 2012 German recommendations for treating rheumatoid arthritis : differences compared to the European standpoint

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

21 March 2017

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

21 March 2017

Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

21 March 2017

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Discontinuation of biologics in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Proposal for a new nomenclature of disease-modifying antirheumatic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

The role of biosimilars in the treatment of rheumatic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 compariso

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Treating rheumatoid arthritis to target: recommendations of an international task force

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Management of RA medications in pregnant patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

The importance of reporting disease activity states in rheumatoid arthritis clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Incorporating considerations of resources use into grading recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

New therapies for treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Clinical efficacy of sulphasalazine--a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 September 2017

Therapies for active rheumatoid arthritis after methotrexate failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Comparison of effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

31 May 2018

Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

The burden of rheumatoid arthritis and access to treatment: health burden and costs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Clinical evaluation of the efficacy of the P2X7purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 November 2018

The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933074

28 November 2018

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204573

21 January 2018

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are Glucocorticoids DMARDs?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing remission in clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of rheumatoid arthritis improvement criteria that include simplified joint counts

1 reference

https://pubmed.ncbi.nlm.nih.gov/24161836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2013-204573

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26859134&oldid=1951219792"